Biotechnology company NewcelX Ltd (Nasdaq: NCEL) on Monday reported positive results from an international collaborative study evaluating advanced biomaterial strategies to support delivery and function of stem cell-derived islets for the treatment of Type 1 Diabetes without the need for immune suppression.

Peer-reviewed research, published in Diabetology, was conducted with academic partners including the University of Technology Sydney, University of Wisconsin-Madison, Monash University, Queensland University of Technology and the Australian Foundation for Diabetes Research. The study assessed engineered scaffolds incorporating extracellular matrix derived from decellularised human pancreas tissue within a removable delivery system.

Results showed that incorporation of extracellular matrix into the scaffold enabled implanted pluripotent stem cell-derived islets to achieve functional performance comparable to encapsulated islets delivered without a scaffold. Findings highlight the importance of biomaterial design and tissue microenvironment in supporting islet function and suggest potential for safer, retrievable delivery configurations in future therapeutic applications.

Research was supported by a Type 1 Diabetes initiative led by Australian Foundation for Diabetes Research, with matched donor funding from the National Stem Cell Foundation of Australia, and additional development funding from Breakthrough T1D, formerly JDRF. NewcelX said the study underpins ongoing development of its IsletRx programme, an investigational stem cell–derived islet therapy designed to restore insulin production without systemic immunosuppression.

Type 1 Diabetes remains a core strategic focus for NewcelX Ltd, which is advancing cell-based regenerative medicine solutions through integration of stem cell biology, biomaterials and immune-protective delivery technologies.

NewcelX reports positive biomaterial study results supporting stem cell islet delivery without immune suppression